Safety of Intradiaphragmatic Delivery of Adeno-Associated Virus-Mediated Alpha-Glucosidase (rAAV1-CMV- <i>hGAA</i> ) Gene Therapy in Children Affected by Pompe DiseaseManuela Corti, Barry J. Byrne, Cristina Liberati et al.|Human Gene Therapy Clinical Development|2017Cited by 118
Assessment of systemic AAV-microdystrophin gene therapy in the GRMD model of Duchenne muscular dystrophySharla M. Birch, Joe N. Kornegay, Brittany A. Fickau et al.|Science Translational Medicine|2023Cited by 68
Long‐term safety and efficacy of AAV gene therapy in the canine model of glycogen storage disease type IaYoung‐Mock Lee, David A. Weinstein, Thomas J. Conlon et al.|Journal of Inherited Metabolic Disease|2018Cited by 27
Toxicology and Pharmacology of an AAV Vector Expressing Codon-Optimized RPGR in RPGR-Deficient Rd9 MiceChunjuan Song, Guojie Ye, Thomas J. Conlon et al.|Human Gene Therapy Clinical Development|2018Cited by 19
Assessment of systemic AAV-microdystrophin gene therapy in the GRMD model of Duchenne muscular dystrophyMichael J. Struharik, Xiaoqing Pan, Amanda K. Bettis et al.|UNC Libraries|2024Cited by 0